Table 2

Microsatellite analysis and clinical status of melanoma patients

Patient numberTumor LOHPlasma LOHAJCC stage at blood drawClinical status at blood drawTotal follow-up (month)Disease progressiona
1+bc4AWDd3.4+
2++4NED10+
3+4AWD14.3+
4++4NED14.7
5++4NED14.9
6+4AWD14.5+
7++4NED8.5+
8+4NED11.4+
9+3NED14.3+
10+3NED13.8
11++3NED14.7
12++3NED12.7
13++4NED14.8
14+3NED12.9+
15+3AWD14.2+
16+3NED7.5+
17+3NED14.5+
18++3NED14.3+
19+3NED14.8+
20+4NED10.6+
21++4AWD1.9+
224AWD9.7
23+4AWD14.8
244AWD9.6
254NED13.6+
26++3NED13.6+
27++3NED14.1
28++3NED12.0
29++4AWD3.4+
30+3NED13.9
31+4NED14.4
32++4AWD14.5+
33++2NED14.9+
34++4NED10.7+
35++4AWD14.2+
36++4AWD15.8+
37++4AWD6.8+
383NED14.8
39++4NED4.5+
40++4AWD3.7+
  • a Disease progression refers to expiration, recurrence, increase in number of metastases or tumor size; yes (+) and no (−).

  • b LOH was detected at least at one locus.

  • c LOH was not detected at any loci.

  • d AWD, alive with disease; NED, no evidence of disease.